Pasithea Therapeutics Corp.
Clinical trials sponsored by Pasithea Therapeutics Corp., explained in plain language.
-
New pill hopes to shrink painful nerve tumors in NF1 patients
Disease control Recruiting nowThis early-stage trial tests a daily pill called PAS-004 in 56 adults with NF1 who have at least one symptomatic, inoperable plexiform neurofibroma. The study has two parts: Part A finds a safe dose, and Part B checks safety and whether the drug can shrink tumors. Participants ta…
Phase: PHASE1 • Sponsor: Pasithea Therapeutics Corp. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New MEK inhibitor PAS-004 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called PAS-004 in people with advanced solid tumors that have certain gene mutations (RAS, NF1, or RAF). The main goal is to see how safe the drug is and what side effects it causes. About 48 participants will take the drug by mouth da…
Phase: PHASE1 • Sponsor: Pasithea Therapeutics Corp. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC